Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.57 |
| ▸ | CASP1 | P29466 | 5/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20211867 | 1.00 | CTSL (0.61) | CTSLSIRT2FOLH1CASP1MME | |
| SCHEMBL6946904 | 1.00 | CTSL (0.61) | CTSLSIRT2FOLH1CASP1MME | |
| Trifluoroacetic Acid SCHEMBL21518543 | 0.94 | CTSL (0.58) | CTSLSIRT2FOLH1CASP1MME | |
| SCHEMBL11153005 | 0.92 | CTSL (0.61) | CTSLSIRT2CASP1MMEECE1 | |
| SCHEMBL4910504 | 0.90 | CTSL (0.60) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL4910499 | 0.90 | CTSL (0.60) | CTSLSIRT2CASP1CTSKTACR1 | |
| SCHEMBL9537095 | 0.89 | CTSL (0.58) | CTSLSIRT2CTSK | |
| SCHEMBL9537091 | 0.89 | CTSL (0.58) | CTSLSIRT2CTSK | |
| SCHEMBL29004082 | 0.89 | CTSL (0.59) | CTSLFOLH1CASP1MMEECE1 | |
| SCHEMBL16063752 | 0.89 | ALDH1A1 (0.58) | CTSLFOLH1CASP1MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-12029738-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240207255-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2024-06-27 | — | — | US | disclosed |
| US-20240076281-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| US-20240066026-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | CELGENE CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | CELGENE CORPORATION (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230341375-A1 | METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE | CELGENE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-20230330086-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | SIGNAL PHARMACEUTICALS, LLC | 2023-10-19 | — | — | US | disclosed |
| EP-4259137-A1 | METHODS OF TREATING BREAST CANCER WITH TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| US-5242679-A | Complexes for imaging tumors | NEORX CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| US-5175343-A | For detection, radiotherapy and radeoimaging of tumors | NEORX CORPORATION (US) | 1992-12-29 | — | — | US | disclosed |
| US-5120526-A | Chelate compounds | NEORX CORPORATION (US) | 1992-06-09 | — | — | US | disclosed |
| US-5037630-A | Chelated polypeptides specific for tumors, improved imaging | NEORX CORPORATION (US) | 1991-08-06 | — | — | US | disclosed |
| US-5021556-A | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides | NEORX CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| US-4897255-A | Metal radionuclide labeled proteins for diagnosis and therapy | NEORX CORPORATION (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0300431-A2 | Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides | NEORX CORPORATION (US) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029738-B2 | Antiproliferative compounds and methods of use thereof | MCL1, NPM1, NFATC1 | CTSL 3121/4885SIRT2 889/4885FOLH1 1624/4885 |
| US-20240066026-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | SLCO1B3, SLCO1B1, SLCO4C1 | CTSL 4336/4885SIRT2 2656/4885FOLH1 1133/4885 |
| US-20240076281-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | CTSL 3310/4885SIRT2 3129/4885FOLH1 1604/4885 |
| US-20230341375-A1 | METHODS FOR TREATING MULTIPLE MYELOMA AND THE USE OF COMPANION BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE | MYADM, BCL6B, BCL6 | CTSL 697/4885SIRT2 1016/4885FOLH1 239/4885 |
| US-20230330086-A1 | ANTIPROLIFERATIVE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | NEK4, AURKB, XPO1 | CTSL 4603/4885SIRT2 601/4885FOLH1 4653/4885 |
| US-11912644-B2 | Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | UMPS, DHPS, NT5C3B | CTSL 3896/4885SIRT2 2519/4885FOLH1 2859/4885 |
| US-20240207255-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, NPM1, NFATC1 | CTSL 3121/4885SIRT2 889/4885FOLH1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.